8. RARE ADULT PARA AND TESTICULAR TUMOURS
Less than 5% of TCs are unrelated to GCNIS and lack 12p alterations [285,286]. These tumours are rare with available literature based on case reports and small retrospective series. Given the rarity of non-germ cell para-/testicular cancers, referral of these cases to specialist units for multidisciplinary discussion including central image and pathology review is highly recommended. As a result of publication bias related to these types of study, the risk of metastatic disease may be less than that reported in the literature.
8.1. Classification
These testicular tumours have a similar presentation as TC and are only identified after histopathologic examination. They are classified according to the WHO Classification of Tumours of the Urinary System and Male Genital Organs [287].
8.2. Spermatocytic Tumours
Spermatocytic tumours are GCTs unrelated to GCNIS. They may show a unique amplification of chromosome 9 corresponding to the DMRT1 gene and are never associated with other forms of GCTs [287].
Spermatocytic tumours are rare, occur exclusively in the testis and do not normally show elevated tumour markers [287]. Previously named “spermatocytic seminomas” they have been recently reclassified as spermatocytic tumours [287]. As those tumours cannot be differentiated from seminoma GCT by FSE, radical orchiectomy is the standard treatment option. Outcomes after TSS or adjuvant treatment is unknown and therefore not recommended [288]. Metastatic disease is very rare, usually associated with ‘sarcomatoid change’ and typically presents at or soon after initial diagnosis with limited survival [288].
8.3. Sex cord-stromal tumours
Sex cord–stromal tumours are relatively uncommon but represent the second largest group of primary testicular tumours after GCT’s [289]. As a small subset of these tumours are clinically malignant, a thorough evaluation of those morphological features associated with malignancy should be performed to guide management. Two or more of the following features are associated with malignant potential: size > 5 cm, infiltrative borders, cytological atypia, three or more mitotic figures per ten high-power fields, vascular invasion and necrosis [289].
8.3.1. Leydig cell tumours
Leydig cell tumours comprise about 4% of adult testicular tumours [290]. These mainly present as localised tumours with metastases occurring in only 2.5% [291]. They may present with hormonal manifestations, including gynaecomastia and more rarely are accompanied by Cushing’s Syndrome [389]. With TSS a local recurrence rate of 7% has been reported although no adjuvant treatment options can be recommended [292]. Several risk factors for metastatic disease have been proposed which may guide image-guided follow-up intensity [292]. Survival of men with metastatic disease is poor but occasional responses to surgical resection, if feasible, and to a lesser extent systemic treatment have been reported [292].
8.3.2. Sertoli cell tumours
Sertoli cell tumours account for approximately 1% of testicular neoplasms [289]. The risk of metastases is unclear. With TSS a local recurrence rate of < 1% has been reported although no adjuvant treatment options can be recommended [293]. Several risk factors for metastatic disease have been proposed which may guide image guided follow-up intensity [293]. Survival of men with metastatic disease is poor although response to surgery has been occasionally reported [293].
8.3.3. Granulosa cell tumour
Granulosa cell tumours, which include adult and juvenile variants, are extremely rare and metastatic potential is unclear [289]. With TSS a local recurrence rate of 5% has been reported although no adjuvant treatment options can be recommended [294]. Whereas metastatic disease has never been reported in juvenile granulosa cell tumours, men with adult type may occasionally present with metastatic disease [294]. Survival of men with metastatic disease is poor although rare instances of response to surgical or systemic treatment has been reported [294].
8.3.4. Thecoma/fibroma group of tumours
These tumours derive from the testicular parenchymal stroma or from the tunica albuginea. They seem to be uniformly benign [289,295].
8.3.5. Paratesticular tumours of the epididymis or spermatic cord
The majority of epididymal masses are benign cystic or inflammatory conditions. Solid epididymal tumours are rare and comprise numerous benign and neoplastic lesions. In the only population-based analyses [296], the majority of neoplastic lesions of the epididymis or spermatic cord were sarcomas, metastases from other organs or primary adenocarcinomas similar to proportions reported in institutional studies [297,298]. Benign lesions, which may comprise the majority in clinical practice include lipomas, adenomatoid tumours leiomyomas and papillary cystadenomas.
Robust criteria to differentiate between neoplastic benign lesions have not been defined although ultrasonography with or without fine needle aspiration [299] MRI [45,300] or surgical exploration with FSE or histopathological confirmation can be considered. No clear recommendation can be provided regarding surgical approach, extent of resection and neo- or adjuvant treatment can be given.
8.4. Mesothelioma of the tunica vaginalis testis
Mesothelioma of the tunica vaginalis testis is a rare but aggressive disease [301]. Beside older age, larger tumour size, presence of necrosis, angiolymphatic invasion or a high mitotic index the only modifiable risk factors represents local recurrence. Therefore, aggressive local treatment with hemiscrotectomy is recommended. No clear recommendation can be given regarding adjuvant treatment. In case of metastatic disease, the median OS is a few months only and multimodal treatment could be considered.
8.5. Follow-up of rare adult para- and testicular cancers
After local surgical treatment is completed, attention turns to follow‐up strategies with the aims of detecting recurrence or secondary cancers at a stage when further curative procedures are possible whilst minimising the burden of follow-up and the potential for over-treatment and concomitant treatment toxicity. Data for rare para- and testicular cancers are limited but recommended follow-up schedules based on published case series have been suggested [302].